Evidence map›Paper›PMID 28438207›Full record

ArticleMicrobial cell factories2017

Large scale validation of an efficient CRISPR/Cas-based multi gene editing protocol in Escherichia coli.

Francesca Zerbini, Ilaria Zanella, Davide Fraccascia, Enrico König, Carmela Irene, Luca F Frattini, Michele Tomasi, Laura Fantappiè, Luisa Ganfini, Elena Caproni and 3 more

Open access · goldAbstract readValidation Study
In one paragraph

Article in Microbial cell factories, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Avian PathogenicVeterinary sciences · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Francesca ZerbiniSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Ilaria ZanellaSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Davide FraccasciaSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Enrico KönigSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Carmela IreneSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Luca F FrattiniSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Michele TomasiSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Laura FantappièSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Luisa GanfiniSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Elena CaproniSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy.
Matteo ParriToscana Life Sciences Scientific Park, Via Fiorentina, 1, 53100, Siena, Italy.
Alberto GrandiToscana Life Sciences Scientific Park, Via Fiorentina, 1, 53100, Siena, Italy.
Guido GrandiSynthetic and Structural Vaccinology Unit, CIBIO, University of Trento, Via Sommarive, 9, Povo, 38123, Trento, Italy. guido.grandi@unitn.it.
University of Trento · ITToscana Life Sciences · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe exploitation of the CRISPR/Cas9 machinery coupled to lambda (λ) recombinase-mediated homologous recombination (recombineering) is becoming the method of choice for genome editing in E. coli. First proposed by Jiang and co-workers, the strategy has been subsequently fine-tuned by several authors who demonstrated, by using few selected loci, that the efficiency of mutagenesis (number of mutant colonies over total number of colonies analyzed) can be extremely high (up to 100%). However, from published data it is difficult to appreciate the robustness of the technology, defined as the number of successfully mutated loci over the total number of targeted loci. This information is particularly relevant in high-throughput genome editing, where repetition of experiments to rescue missing mutants would be impractical. This work describes a "brute force" validation activity, which culminated in the definition of a robust, simple and rapid protocol for single or multiple gene deletions.

resultsWe first set up our own version of the CRISPR/Cas9 protocol and then we evaluated the mutagenesis efficiency by changing different parameters including sequence of guide RNAs, length and concentration of donor DNAs, and use of single stranded and double stranded donor DNAs. We then validated the optimized conditions targeting 78 "dispensable" genes. This work led to the definition of a protocol, featuring the use of double stranded synthetic donor DNAs, which guarantees mutagenesis efficiencies consistently higher than 10% and a robustness of 100%. The procedure can be applied also for simultaneous gene deletions.

conclusionsThis work defines for the first time the robustness of a CRISPR/Cas9-based protocol based on a large sample size. Since the technical solutions here proposed can be applied to other similar procedures, the data could be of general interest for the scientific community working on bacterial genome editing and, in particular, for those involved in synthetic biology projects requiring high throughput procedures.

Indexed as

CRISPR-Cas SystemsGene EditingMultigene FamilyEscherichia coliGene DeletionGenome, BacterialHomologous RecombinationMutagenesisRecombinasesRNA, Guide, CRISPR-Cas SystemsSynthetic BiologyRecombinasesRNA, Guide, CRISPR-Cas SystemsCRISPR-Cas9High-throughput genome editingSynthetic biology

Identifiers

PMID28438207
PMCPMC5404680
OpenAlexW2609834193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.